Fortis Life Sciences has acquired Abcore, a San Diego, California, USA primarily based antibody discovery platform specializing in nanobody expertise. With the addition of Abcore, Fortis extends its capabilities into the antibody discovery market serving biopharma clients creating antibody and nanobody-based therapeutics.
Abcore is a strong addition to the Fortis portfolio and deepens our antibody product and repair capabilities. We’re notably optimistic concerning the potential of nanobody applied sciences in therapeutic and diagnostic functions. Our acquisition of Abcore aligns completely with Fortis’ purpose of partnering with and investing in world-class life sciences firms in search of a strategic development associate.”
Brian Kim, Chief Govt Officer, Fortis, Remarked on the Partnership
“We’re enthusiastic about accelerating Abcore’s development as a part of the Fortis household,” added David Barraclough, Chief Govt Officer of Abcore. “Fortis shares our dedication to scientific discovery, innovation, and customer support and is the best associate for Abcore as we develop our technical capabilities and produce new services to market.”
Our partnership with Fortis will present Abcore with the business and operational infrastructure needed for us to concentrate on creating high-quality merchandise and higher serving our clients.”
Jennifer Johnson, President of Abcore
Pivotal Scientific Ltd. acted because the unique company advisor to Abcore.
#Fortis #Life #Sciences #acquires #Abcore #chief #nanobody #applied sciences